drugset / Trial / NCT04964453
A Study in Healthy Men to Test How BI 474121 is Tolerated
RandomizedSequentialQuadruple-blindTreatment
Summary
Safety, tolerability, and pharmacokinetics of BI 474121 will be assessed in healthy Japanese male using single rising oral doses in order to provide the basis for an ongoing clinical development of BI 474121 for the treatment of cognitive impairment in patients with Alzheimer's Disease and schizophrenia.
Timeline
- Start
- 2021-07-21
- Primary completion
- 2021-11-11
- Completion
- 2021-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 474121 | Unknown | 2.5 mg | Oral |
| Subject | BI 474121 | Unknown | 5 mg | Oral |
| Subject | BI 474121 | Unknown | 10 mg | Oral |
| Subject | BI 474121 | Unknown | 20 mg | Oral |
Indications
No indication recorded.